Pro Share Advisors LLC Apellis Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

  • $36.7 Billion
  • Q1 2024

A detailed history of Pro Share Advisors LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 8,452 shares of APLS stock, worth $311,709. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,452
Previous 7,571 11.64%
Holding current value
$311,709
Previous $453,000 9.49%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024
BUY
$55.39 - $72.47 $48,798 - $63,846
881 Added 11.64%
8,452 $496,000
Q4 2023

Feb 14, 2024
SELL
$37.14 - $64.82 $4,493 - $7,843
-121 Reduced 1.57%
7,571 $453,000
Q3 2023

Nov 13, 2023
BUY
$23.65 - $89.22 $3,713 - $14,007
157 Added 2.08%
7,692 $292,000
Q2 2023

Aug 10, 2023
SELL
$76.68 - $93.31 $877,142 - $1.07 Million
-11,439 Reduced 60.29%
7,535 $686,000
Q1 2023

May 11, 2023
SELL
$46.59 - $66.96 $170,659 - $245,274
-3,663 Reduced 16.18%
18,974 $1.25 Million
Q4 2022

Feb 02, 2023
BUY
$43.24 - $61.04 $67,843 - $95,771
1,569 Added 7.45%
22,637 $1.17 Million
Q3 2022

Nov 04, 2022
BUY
$44.76 - $69.66 $114,496 - $178,190
2,558 Added 13.82%
21,068 $1.44 Million
Q2 2022

Aug 01, 2022
SELL
$35.07 - $59.21 $183,591 - $309,964
-5,235 Reduced 22.05%
18,510 $836,000
Q1 2022

May 10, 2022
SELL
$35.46 - $54.12 $191,696 - $292,572
-5,406 Reduced 18.54%
23,745 $1.21 Million
Q4 2021

Feb 08, 2022
BUY
$30.74 - $49.16 $69,380 - $110,954
2,257 Added 8.39%
29,151 $1.38 Million
Q3 2021

Nov 12, 2021
SELL
$31.4 - $69.84 $138,756 - $308,622
-4,419 Reduced 14.11%
26,894 $886,000
Q2 2021

Aug 13, 2021
BUY
$40.9 - $64.9 $169,080 - $268,296
4,134 Added 15.21%
31,313 $1.98 Million
Q1 2021

May 14, 2021
BUY
$40.8 - $57.39 $89,188 - $125,454
2,186 Added 8.75%
27,179 $1.17 Million
Q4 2020

Feb 09, 2021
BUY
$30.79 - $57.2 $167,682 - $311,511
5,446 Added 27.86%
24,993 $1.43 Million
Q3 2020

Nov 13, 2020
SELL
$25.89 - $33.65 $17,605 - $22,882
-680 Reduced 3.36%
19,547 $590,000
Q2 2020

Aug 03, 2020
BUY
$24.8 - $38.49 $162,960 - $252,917
6,571 Added 48.12%
20,227 $661,000
Q1 2020

May 15, 2020
SELL
$17.91 - $44.33 $121,429 - $300,557
-6,780 Reduced 33.18%
13,656 $366,000
Q4 2019

Feb 12, 2020
SELL
$22.1 - $30.8 $51,117 - $71,240
-2,313 Reduced 10.17%
20,436 $626,000
Q3 2019

Nov 12, 2019
BUY
$24.09 - $32.18 $11,346 - $15,156
471 Added 2.11%
22,749 $548,000
Q2 2019

Aug 13, 2019
SELL
$18.0 - $25.34 $12,906 - $18,168
-717 Reduced 3.12%
22,278 $565,000
Q1 2019

May 15, 2019
BUY
$12.81 - $19.82 $1,626 - $2,517
127 Added 0.56%
22,995 $448,000
Q4 2018

Feb 14, 2019
BUY
$11.47 - $18.71 $262,295 - $427,860
22,868 New
22,868 $302,000

Others Institutions Holding APLS

# of Institutions
335
Shares Held
109M
Call Options Held
1.26M
Put Options Held
1.14M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $4.05B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email